CA
FRTX

Clearstead Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Clearstead Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 1474
2021
Q4 		$0 Hold
1
– – ﹤0.01% 1461
2021
Q3 		$0 Hold
1
– – ﹤0.01% 1420
2021
Q2 		$0 Hold
1
– – ﹤0.01% 1318
2021
Q1 		$0 Hold
1
– – ﹤0.01% 1200
2020
Q4 		$0 Hold
1
– – ﹤0.01% 1035
2020
Q3 		$0 Hold
1
– – ﹤0.01% 937
2020
Q2 		$0 Hold
1
– – ﹤0.01% 847
2020
Q1 		$0 Buy
+1
New +$78 ﹤0.01% 788

Other funds holding FRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JSW
Journey Strategic Wealth Summit, New Jersey $4.03B AUM 33.12% 1-Year Est. Return

Clearstead Advisors's FRTX Position: Q1 2022 in Review

Clearstead Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q1 2022, closing a stake of 1 share.

Clearstead Advisors first reported a position in FRTX in Q1 2020 and held it in 8 quarters. The position peaked at $0 in Q4 2021. 22 funds tracked by Wall St. Rank hold FRTX as of Q1 2022.

  • Clearstead Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Clearstead Advisors sold 1 Fresh Tracks Therapeutics, Inc. Common Stock share in Q1 2022.
  • Clearstead Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2020 and held it in 8 quarters.
  • Clearstead Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $0 in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Clearstead Advisors's 13F filing for Q1 2022, filed 4 May 2022.